Pure Global

TGRX-326 Pharmacokinetic Drug Interaction - Trial NCT06294561

Access comprehensive clinical trial information for NCT06294561 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 32 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06294561
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06294561
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
TGRX-326 Pharmacokinetic Drug Interaction
An Open-label, Two-cycle, Single Sequence, Self-controlled Study Evaluating Effects of Oral Itraconazole or Efavirenz on Pharmacokinetic Profiles of TGRX-326

Study Focus

Itraconazole+TGRX-326

Interventional

drug

Sponsor & Location

Shenzhen TargetRx, Inc.

Nanjing, China

Timeline & Enrollment

Phase 1

Mar 04, 2024

Jun 30, 2024

32 participants

Primary Outcome

Plasma Tmax,Plasma Cmax,Plasma AUC(0-t),Plasma AUC(0-inf),T1/2,Plasma volume of distribution (Vz/F),Plasma clearance (CL/F)

Summary

This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A
 inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated
 for treatment of Non-small cell lung cancer.

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06294561

Non-Device Trial